Loading
institutionsInstitution
ACCELERATE
ACCELERATE is a Brussels-based forum where children's cancer doctors, drug companies, the EMA and FDA and parents agree which new cancer drugs should be tested in children and how, so that medicines developed for adults are not left untested in childhood cancers.
Also called: ACCELERATE platformACCELERATE Paediatric Oncology Platform
Overview
Founded in 2013 as a joint initiative of SIOP Europe, ITCC, the European Society for Paediatric Oncology's parent groups and industry, ACCELERATE is a multi-stakeholder platform for paediatric oncology drug development. Its Paediatric Strategy Forums, held with the EMA and the FDA Oncology Center of Excellence, take a mechanism of action (ALK, MEK, BCL2, CDK4/6, ADCs, immunotherapy, radiopharmaceuticals) and agree which products should advance in children and how, an approach that feeds directly into RACE Act and EU Paediatric Regulation obligations. Other workstreams are Fit-for-Filing (making academic trial data acceptable for regulatory submissions), the Long-Term Follow-Up initiative for children on novel agents, the ACCELERATE Paediatric Oncology Master Protocol concept, and the Paediatric Oncology Preclinical Proof-of-Concept programme.
Location
Brussels, BE
Type
consortium
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#323 · 20 points (0 Newsweek + 0 NCI + 20 from 10 linked objects) · ranking
- Paediatric Strategy Forums (with EMA and FDA)
- Fit-for-Filing
- Long-Term Follow-Up of children on novel agents
- Pediatric Oncology Preclinical Proof-of-Concept
- Annual ACCELERATE conference
Gilles Vassal
Board member, Oncopolicy
Paediatric oncologyPaediatric drug developmentOncology policy
Gustave Roussy paediatric oncologist and past SIOPE president who leads its oncopolicy work and helped shape European paediatric medicines regulation.
Nicole Scobie
Chair of the Board of Directors, ACCELERATE
Patient advocacyPaediatric oncology drug developmentMulti-stakeholder governance
Patient advocate from Switzerland who chairs the board of ACCELERATE, the European multi-stakeholder platform speeding up new medicines for children and adolescents with cancer.
Similar pages
- InstitutionHistiocyte Society
Shares Rare and paediatric cancers without markets and the tag paediatric.
- CancerWilms tumour (nephroblastoma)
Shares Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Neuroblastoma (paediatric) and the tag paediatric.
- CancerHepatoblastoma
Shares Neuroblastoma (paediatric) and the tag paediatric.
- TrialACTION
Shares RACE for Children Act, Diffuse midline glioma, H3 K27-altered (including DIPG), Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Rare and paediatric cancers without markets and the tag paediatric.
- TrialNCI-COG Pediatric MATCH (APEC1621)
Shares Innovative Therapies for Children with Cancer (ITCC), RACE for Children Act, Diffuse midline glioma, H3 K27-altered (including DIPG), Paediatric low-grade glioma and the tag paediatric.
- TrialTADPOLE (CDRB436G2201)
Shares RACE for Children Act, Paediatric low-grade glioma, Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first and the tag paediatric.
- TrialFIREFLY-1
Shares RACE for Children Act, Paediatric low-grade glioma, Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first and the tag paediatric.
- TrialEURAMOS-1
Shares SIOP Europe (European Society for Paediatric Oncology), Paediatric oncology roadmap: cooperative-group cures → engineered immunity → drugs developed for children first, Rare and paediatric cancers without markets and the tag paediatric.